Logo

BLRX

BioLineRx Ltd.

BLRX

BioLineRx Ltd. • NASDAQ
$3.47 ▲ 0.73% (+0.03)
Market Cap $15.10 M
52w High $14.80
52w Low $2.30
Dividend Yield 0%
P/E -0.58
Volume 9.70K
Outstanding Shares 4.35M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $4.943M ▲ $-7.953M ▼ $-5.822M ▼ -117.783% ▲ $-1.47 ▼ $0 ▲
Q2-2025 $304K ▲ $2.535M ▼ $-3.94M ▼ -1.296K% ▼ $-1 ▼ $-3.488M ▼
Q1-2025 $255K ▼ $2.612M ▼ $5.127M ▲ 2.011K% ▲ $0.065 ▲ $5.712M ▲
Q4-2024 $11.749M ▲ $10.086M ▲ $-3.187M ▲ -27.126% ▲ $-0.041 ▲ $3.1M ▲
Q3-2024 $4.943M $9.508M $-5.822M -117.783% $-0.073 $-3.357M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $28.159M ▲ $43.267M ▼ $23.195M ▲ $20.072M ▼
Q1-2025 $26.369M ▲ $43.51M ▲ $22.648M ▼ $20.862M ▲
Q4-2024 $19.562M ▼ $38.906M ▼ $25.445M ▼ $13.461M ▲
Q3-2024 $29.173M ▼ $52.742M ▼ $44.237M ▼ $8.505M ▼
Q2-2024 $40.06M $64.596M $50.615M $13.981M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-3.94M ▼ $-177K ▲ $-3.704M ▲ $1.602M ▼ $-1.847M ▼ $-177K ▲
Q1-2025 $5.127M ▲ $-2.591M ▲ $-8.177M ▼ $9.45M ▲ $-1.4M ▼ $-2.591M ▲
Q4-2024 $-3.187M ▲ $-8.61M ▲ $11.157M ▲ $-1.109M ▲ $1.6M ▲ $-8.605M ▲
Q3-2024 $-5.822M ▼ $-9.825M ▲ $10.175M ▲ $-1.218M ▼ $-787K ▼ $-9.825M ▲
Q2-2024 $484K $-11.329M $-8.645M $23.879M $3.633M $-11.356M

Five-Year Company Overview

Income Statement

Income Statement BioLineRx still looks like a classic development‑stage biotech: very little revenue so far and recurring losses each year. The first signs of product revenue have begun to appear, likely tied to APHEXDA, but they are still too small to cover ongoing research, overhead, and partnership costs. Losses have narrowed somewhat recently, suggesting tighter cost control and some benefit from out‑licensing, but the business remains far from self‑funding and depends on external capital and milestone payments rather than steady product sales.

Balance Sheet

Balance Sheet The balance sheet is small and quite lean, reflecting a focused R&D company rather than a diversified pharma business. Cash is limited, but recent restructuring and partnerships have extended the expected cash runway, reducing immediate pressure. There is some debt, but not at a level that appears overwhelming; the bigger issue is the company’s small equity base after years of cumulative losses. Reverse stock splits also highlight that the share count and market price have had to be managed to stay exchange‑compliant. Overall, financial flexibility exists but is constrained, and the company remains sensitive to setbacks or delays in its pipeline.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, as the company spends on R&D, overhead, and clinical programs with only modest inflows from collaborations and early product sales. Capital spending on physical assets is minimal, which is typical for a biotech focused on drug development rather than manufacturing. Free cash flow is therefore meaningfully negative but more stable after the shift to a leaner model and the out‑licensing of APHEXDA’s commercialization. Continued progress depends on disciplined expense management, timely partner payments, and, over time, either stronger royalty streams or new financing.

Competitive Edge

Competitive Edge BioLineRx competes in specialized oncology and rare disease niches, where strong science and regulatory execution matter more than sales muscle. Its main commercial asset, APHEXDA, is already approved for stem cell mobilization and has shown a clear performance edge versus the long‑time standard competitor, which helps explain its early uptake. Long patent life and orphan drug protections strengthen the moat around key products. At the same time, the company is small, heavily reliant on partners for commercialization, and up against much larger pharmaceutical players and generic competitors. Its competitive position is promising but still fragile, tied to a limited set of assets and the success of collaborations.

Innovation and R&D

Innovation and R&D Innovation is the core of BioLineRx’s identity. APHEXDA is an approved, differentiated CXCR4 inhibitor with potential to expand into new cancer and gene‑therapy related uses, which could significantly broaden its impact if trials succeed. GLIX1 represents a first‑in‑class approach to targeting DNA damage response in difficult cancers like glioblastoma, with the added advantage of crossing the blood‑brain barrier—a rare and valuable trait. Strong patent coverage, orphan designations, and a joint‑venture model help protect these assets and share risk. The company is now operating as a streamlined R&D engine, looking to in‑license more assets, but its pipeline is still relatively concentrated, so clinical and regulatory outcomes for a few key programs will be critical.

Summary

BioLineRx is in the middle of a strategic shift from being a small commercial biopharma to a focused R&D company anchored by one approved drug and a high‑potential early‑stage oncology asset. Financially, it remains loss‑making with negative cash flow, a modest cash cushion, and a small equity base, though partner deals and cost cuts have improved visibility over the next few years. Competitively, it has a meaningful foothold in a specialized market and strong intellectual property, but it is still a niche player facing far larger rivals and significant development risk. The long‑term story now hinges on three pillars: expanding APHEXDA into new uses, successfully advancing GLIX1 and other future pipeline assets, and maintaining financial discipline while doing so. Outcomes in those areas will largely determine whether the company’s scientific promise translates into durable value over time.

NEWS

November 24, 2025 · 7:00 AM UTC

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 18, 2025 · 7:00 AM UTC

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Read more

November 17, 2025 · 7:00 AM UTC

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Read more

September 29, 2025 · 7:00 AM UTC

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Read more